RepliCel Life Sciences Inc. Stock Toronto S.E.
Equities
RP
CA76027P4006
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CAD | -.--% | -21.43% | -15.38% |
Sales 2022 | 354K 258K | Sales 2023 | 354K 258K | Capitalization | 3.87M 2.82M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 9.26 x |
Net Debt 2022 | 300K 218K | Net Debt 2023 | 797K 580K | EV / Sales 2023 | 13.2 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-11.3
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.48% |
6 months | -42.11% | ||
Current year | -15.38% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 10-12-21 |
Peter Lewis
BRD | Director/Board Member | 69 | 11-05-26 |
Rolf Hoffmann
FOU | Founder | 63 | - |
1st Jan change | Capi. | |
---|---|---|
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- REPC.F Stock
- RP Stock